AbbVie Completes $10.9B Acquisition of Apogee Therapeutics
AbbVie closed its acquisition of Apogee Therapeutics, paying shareholders $135.11 per share in cash for a total equity value of about $10.9 billion.
Read the full coverage, free
We only link to sources you can read without a subscription. How we check.